Stem Cell Theranostics and CapellaBio established a cardio-oncology collaboration to discover novel drug therapies to prevent cardiotoxicity associated with various oncology drugs.
By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs.
The first collaborative program is focused on discovering cardioprotective drugs to prevent anthracycline-induced cardiotoxicity. There is currently only one FDA-approved agent, Dexrazoxane, but this has limited indication approval and has not been widely used due to concerns that it may interfere with the anti-tumor activity of anthracyclines. Novel cardioprotectants with improved efficacy and safety profiles that could be used across multiple indications would offer significant clinical benefit.
